BevCanna Enterprises



BetterLife to Present at the Emerging Growth Conference on September 15, 2021

BetterLife Enters Research Agreement with Medical College Wisconsin for TD-0148A Neurological Receptor Studies

BetterLife Initiates Preclinical Study of AP-003 (rhIFNa2b) against Delta Variant of SARS-CoV-2

BetterLife Receives Approval to Conduct COVID-19 Randomized Placebo-Controlled Trial with Pontificia Universidad Católica de Chile

BetterLife-Carleton University Research Team Secure Mitacs Accelerate Funding to Study the Therapeutic Effect of TD-010 in Chronic Anxiety

CEO Presenting on the Emerging Growth / Investors Hub Joint Conference on July 21; Register Now

BetterLife to Present at the Emerging Growth Conference

Early Results of BetterLife Preclinical Study Showing AP-003 (rhIFNa2b) has Similar Potent Efficacy Against Different Variants of COVID-19

BetterLife Provides H1 2021 Progress Update

BetterLife Announces Exercise of Over-Allotment Option in Public Offering

BetterLife Secures Mitacs Funding in Collaboration with Carleton University Research Team for TD-0148A Preclinical Depression Studies

BetterLife Pharma Engages Global Financial and Corporate Communications Agency

BetterLife Pharma to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th

BetterLife Pharma Retains Proactive Investors and Psychedelic Finance for Market Awareness

BetterLife Closes $2.61 Million Marketed Public Offering

BetterLife Pharma Appoints Henri Sant-Cassia of The Conscious Fund to its Board of Directors

BetterLife Announces Marketed Public Offering of Units for up to $2.6 Million

BetterLife Closes $6.325 Million Bought Deal Public Offering of Units, Including Full Exercise of the Over-Allotment Option

BetterLife Announces $5.5 Million Bought-Deal Public Offering of Units

BetterLife Announces Closing of a Non-Brokered Private Placement

BetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent Drug Diversion of LSD and Other Psychedelic Drugs

Former FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory Advisor

BetterLife Added to Horizons Psychedelic Stock Index ETF

BetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology Studies

BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003

BetterLife Enters Research Agreement with Carleton University for TD-0148A Depression Studies

BetterLife Engages Eurofins CDMO for Next Generation Psychedelic TD-0148A Manufacturing

BetterLife to Present at the Emerging Growth Conference on February 17, 2021

BetterLife Files Patent Protection on Dihydrohonokiol-B for Treatment of Anxiolytic Use Disorder

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon Formulation to be Developed to Treat Early Stage Covid-19 Cases